Social Icons

Showing posts with label Bullion Premium. Show all posts
Showing posts with label Bullion Premium. Show all posts

Monday 6 August 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

expr:content='data:blog.blogId' itemprop='blogId'/> CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 06 August 2018

capitalstars

CS OPENING BELL:
NIFTY SPOT UP 61@11422
SENSEX SPOT UP 237 @37793
BANK NIFTY FUTURES SPOT UP 208@ 27984
                                                                     HAPPY TRADING!


CS NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH
RES2: 11500
RES 1:11440
SUP1:11260
SUP2:10910

CS BANK NIFTY FUTURES (JUNE ) OVERVIEW

TREND BULLISH
RES 2: 28100
RES 1: 27880
SUP1: 27400
SUP2: 27200

visit us: www.capitalstars.com/


call us:

9977499927
7440449744

Get more details here:-

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

Saturday 28 July 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

Capitalstars update:Gold, silver add more losses on global cues

CAPITALSTARS
Gold extended its slide for the third straight week and prices drifted lower by Rs 190 to end at Rs 30,780 per 10 grams at the bullion market taking weak cues from overseas markets and fall in demand from local jewellers at the domestic spot market. Silver, in range-bound movements, eased by Rs 30 to Rs 39,225 per kg due to reduced offtake by industrial units and coin makers.
Traders said sentiment remained bearish in sync with the weak trend and considerable fall in demand from local jewellers and retailers at domestic spot market.
Globally, gold ended the week lower at USD 1,223.20 an ounce and silver at USD 15.47 an ounce in New York.
Diversion of funds towards the record-breaking domestic equity markets too weighed on the gold prices, they added.
In the national capital, gold of 99.9 per cent and 99.5 per cent purity started the week on a subdued note and day-to-day increased selling, triggered by a weak global trend, slipped to Rs 30,740 and Rs 30,590 per ten grams respectively, before ending at Rs 30,780 and Rs 30,630 per ten grams, showing a fall of Rs 190 each.
Sovereign, however, moved in a narrow range in scattered deals and pegged at the last level of Rs 24,700 per piece of eight grams.
In line with overall trends, silver ready also ended the week marginally lower by Rs 30 to Rs 39,225 per kg and weekly-based delivery by Rs 130 to Rs 38,325 per kg.
Silver coins, too, dropped by Rs 1,000 to Rs 74,000 for buying and Rs 75,000 for selling of 100 pieces.
visit us: www.capitalstars.com/


call us:

9977499927

7440449744


Get more details here:-

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

Tuesday 10 July 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 10 JULY 2018

capitalstars



CS OPENING BELL:
NIFTY SPOT UP 59@ 10,912
SENSEX SPOT UP 204@ 36139
BANK NIFTY FUTURES SPOT UP 142@ 26,855
                                                                                                  HAPPY TRADING!

CS NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH
RES2: 11100
RES 1:10950
SUP1:10810
SUP2:10700 

CS BANK NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH
RES 2: 27100
RES 1: 26980
SUP1: 26600
SUP2: 26400

call on:9977499927


O731-6690000

Get more details here:-

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647


Wednesday 9 May 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 09 MAY 2018

capitalstars
CS OPENING BELL:
NIFTY SPOT DOWN 7 @ 10709
SENSEX UP 8 @ 35221
BANK NIFTY FUTURES DOWN 33  @ 26009
HAPPY TRADING!!!!!!!!!!!


CS NIFTY FUTURES (MAY ) OVERVIEW

TREND BEARISH
RES2: 10850
RES 1:10770
SUP1:10650
SUP2:10600


CS BANK NIFTY FUTURES (MAY ) OVERVIEW

TREND BEARISH
RES 2: 26250
RES 1: 26150
SUP1: 25900
SUP2: 25800

visit us: www.capitalstars.com/



call on:9977499927

O731-6690000


Get more details here:-

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.



CapitalStars Investment Adviser: SEBI Registration Number: INA000001647



Tuesday 30 January 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

Capitalstars Updates: Top Corporate News :- 30 Jan 2018

Capitalstars Updates:  Top Corporate News

Top Headlines Of The Day:- 30 Jan 2018

Jubilant receives ANDA approval for Clonidine Hydrochloride ER Tablets
KPIT and Birlasoft to come together to create two entities
Mylan and Biocon receive positive CHMP opinion for Insulin Glargine
Amber Enterprises lists at 38% premium to issue price
HCL Tech gets 5-year order from Cadent for IT Infra services

Jubilant receives ANDA approval for Clonidine Hydrochloride ER Tablets
Jubilant Life Sciences has announced that its material wholly owned subsidiary Jubilant Pharma Limited has received Abbreviated New Drug Application (ANDA) final approval for Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg. This is a generic version of Kapvay of Concordia. It is used for the treatment of attention deficit hyperactivity disorder (ADHD).
As on December 31, 2017, Jubilant had a total of 86 ANDAs for Oral Solids filed in the US of which 56 had been approved and 12 Injectable filings of which 10 had been approved. This is the eighth USFDA approval in FY18.

Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg had annual sales of ~USD 66 million in the US as per IMS MAT Jun 2017. 

KPIT and Birlasoft to come together to create two entities
KPIT Technologies had informed the exchanges that its board had approved a draft composite scheme for amalgamation of Birlasoft (India) with KPIT. The second leg of the transaction would involve demerger of the engineering business of the company into KPIT Engineering Limited (KEL), a wholly owned subsidiary of the company and will be renamed as KPIT Technologies Limited.
According to the arrangement, shareholders of Birlasoft will receive 22 equity shares of the combined KPIT -Birlasoft for every nine equity shares of Birlasoft. the combined KPIT-Birlasoft will be engaged in the ITSS Business, and pursuant to the Proposed Demerger, KEL's shares will be listed and shareholders of combined KPIT-Birlasoft will receive one share of KEL for each share they hold in the combined KPIT-Birlasoft.

Mylan and Biocon receive positive CHMP opinion for Insulin Glargine
Biocon has announced that it, along with its partner Mylan, has received a positive opinion from Europen Medical Agency’s (EMA) - Committee for Medicinal Products for Human Use (CHMP) - for insulin Glargine. CHMP has also recommended approval to Insulin Glargine, which will be sold under brand Semglee.
There are ~60m people affected by diabetes in Europe with an increasing prevalence in the region. Insulin Glargine is a biosimilar, which will be available for commercialization once it receives EMA approval.
Biocon and Mylan are also awaiting approval for Insulin Glargine in Australia, Canada, and the US and are planned for key Emerging Markets.

Amber Enterprises lists at 38% premium to issue price
Amber Enterprises listed at a significant premium of 38% to its issue price of Rs855-859 and is currently trading at Rs1, 187.2.
The IPO offer consisted of Fresh Issue of 55.3 lakh shares (aggregating up to ~Rs475cr) at the upper end of the price band. It also includes an offer for sale of up to 14.6 lakh shares (Rs125cr) by the promoters. The issue proceeds will be used for pre-payment or repayment of borrowings (~Rs400cr) and for other general corporate purposes (~Rs75cr).

HCL Tech gets 5-year order from Cadent for IT Infra services
HCL Technologies (HCL) announced a five-year IT infrastructure services and application management contract with Cadent, the UK’s largest gas distribution network. The ground-breaking ‘cloud first’ multi-service deal will see HCL provide integrated public cloud hosting and SAP and Application Maintenance Services, including the migration of a significant applications portfolio to Amazon Web Services (AWS) public cloud. In addition, HCL will provide IT Service Management, Service Desk and Managed Workplace Services.
HCL will deliver these services to support Cadent’s business operations which distributes gas to 11 million homes and businesses in the North West, Midlands, East and South East of England. HCL will provide MWS support to approximately 4,500 staff; including 3,500 field based-engineers who work across the company’s 65 regional depots.

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647





Monday 29 January 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

Capitalstars Updates: Top Corporate News :- 29 Jan 2018

Capitalstars Updates:  Top Corporate News
Top Headlines Of The Day :- 29 Jan 2018
Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
DLF is looking to launch QIP of shares by April, 2018
Idea Cellular seeks government approval for raising FDI limit to 100%
Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
DMart rallies 5% after announcing Q3FY18 results. In Q3FY18, its revenue grew by 22.6% yoy to Rs4, 095cr. EBITDA came in at Rs422cr, up 46.3% yoy . EBITDA margin expanded by 167bps yoy to 12.3% due to an improvement in sales mix and efficiency of centralized procurement. Adjusted PAT increased by 65.8% yoy to Rs252cr.
Board has also approved acquisition of 50.8% paid-up share capital of Avenue E-Commerce Limited for Rs49.2cr. Post-acquisition it will become wholly owned subsidiary. Heavy discounts to attract price sensitive customers and losses of the e-commerce entity will offset the margin gains.


Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Cipla, Aurobindo and Strides Shasun have received final approval for their Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the USFDA. This is a generic version of Gilead Sciences' Viread Tablets, 300mg which is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adults. The final approval means that product is available for immediate commercialization in the US.
Viread 300mg tablets had annual US sales of approximately $725-750mn as per IMS Health. An orange book search on USFDA website indicates that Aurobindo, Cipla, Teva, Macleods Pharmaceuticals and Strides Shasun, all have received approval for this drug on January 26, 2018. Approval for five different filers on the same day is likely to see competition for the Viread 300mg tablets.


Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
Havells is setting-up a new facility at Ghiloth, Neemrana, Rajasthan to manufacture consumer durables, as per the BSE filing. The total estimated cost for the project is Rs360cr (ex-land cost, as the company already owns the land), spread over a period of 3 years. The total investment will be funded through a mix of internal accruals and borrowings. Company expects to start the production from Q3FY19E.
For this investment, the company will be entitled to investment subsidy under the M-SIPS (Modified Special Incentive Package Scheme) introduced by MEITY and also for various tax/ levies and other benefits from the State Government of Rajasthan.


DLF is looking to launch QIP of shares by April, 2018
DLF is looking to launch its qualified institutional placement (QIP) of shares by April 2018, according to a media report.
DLF has already received approval from shareholders to sell 173-million equity shares, which will be determined by the formula laid down by the market regulator Securities and Exchange Board of India. The company may raise Rs4500-5000cr from the QIP.


Idea Cellular seeks government approval for raising FDI limit to 100%
Telecom operator Idea Cellular has made an application to the DIPP (Department of Industrial Policy and Promotion) for raising the FDI limit in Idea to 100%. Foreign investors holdings in Idea Cellular stood at ~27% stake as on December 2017. While 100% FDI is allowed in telecom companies, investments under the automatic route are allowed up to 49%.
At present, Idea Cellular is in the process of merging its telecom business with the Indian unit of Vodafone. As per latest industry data from Trai, Idea and Vodafone jointly have 40.5cr mobile subscribers. This would potentially give the joint entity the largest subscriber base in the Indian telecom segment. Vodafone is expected to hold around 47.5% stake in the merged entity and rest will be owned by Idea and its promoter Aditya Birla Group.


Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647




Friday 27 October 2017

expr:content='data:blog.blogId' itemprop='blogId'/>

PERFORMANCE OF THE DAY - 27 Oct 2017

STOCK FUTURES:

FUTURES INTRADAY:
BUY KPIT FUT 2ND TG 
BUY HERO MOTO FUT 1ST TG 

PREMIUM FUTURES:
BUY APOLLOTYRE FUT 2ND TG 

NIFTY FUTURES:
INDEX OPTION CALL

OPTION
BUY SUNPHARMA CALL 560 NOV 3RDTG 

OPTION PREMIUM
IOC 420 PUT NOV BUY CALL RECENT MADE HIGH OF 25.45 BOOK PARTIAL PROFIT NEAR ITCMP-25.25,AND HOLD 

STOCK CASH

STOCK CASH INTRADAY
BUY RADICO IN CASH 3RDTG 
BUY RECLTD IN CASH 1ST TG 

STOCK CASH  PREMIUM:
BUY TATAGLOBAL IN CASH HOLD FOR TOMORROW
RECLTD BOUGHT ON 25TH OCT NR 163 CALL ON FIREEEE 3RD TG ALMOST ACHIEVED, HIGH 173.25 BOOK FULL PROFIT
IRB INFRA IN CASH BUY CALL RECENT MADE HIGH OF 241.65 BOOK 50% PROFIT NEAR IT AND 2ND TG 248 ,

STOCK SUPER CASH PREMIUM
BUY UBL IN CASH BUY CALL 3RD TG 
BUY SRTRANSFIN IN CASH 2ND TG 
ENGINERSIN IN CASH ON FIREEEEEEEEEEE OUR 3RD TGT 177 ACHIEVED, BOOK FULL PROFIT NEAR TO IT,
ENGINERSIN IN CASH 2ND BUY CALL  ON FIREEEEEEEEEEE OUR 3RD TGT 187 ALMOST ACHIEVED, BOOK FULL PROFIT NEAR TO IT,

EQUITY KING CALL
MARUTI FUT NOV MADE HIGH 8097 NR FINAL TGT 8100 BOOK FULL PROFIT NR IT
ENGINERSIN FUT BOUGHT NR 157.5 FINAL TGT 160.5 ACHIEVED BOOK FULL SUPER PROFIT NR IT

OPTION STRATEGY
BUY INFY 960 CALL NOV  HOLD FOR TOMORROW

HNI CASH CALL
RADICO IN CASH BUY CALL MADE HIGH OF 228.80 BOOK PARTIAL PROFIT NEAR ITCMP-228.25, AND FINAL TG 275

HNI FUTURE CALL
BUY TVS MOTORS FUTURE NOV HOLD FOR TOMORROW

HNI OPTION CALL
MARUTI CALL 8100 BOUGHT NR 219 MADE HIGH 259.7 NR FINAL TGT 260 BOOK FULL PROFIT NR IT

CPE FUTURE CALL
BPCL NOV FUTURES BUY CALL RECENT MADE HIGH OF 545.10 BOOK 50% PROFIT NEAR IT,



Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Thursday 20 August 2015

expr:content='data:blog.blogId' itemprop='blogId'/>

Corporate News For Today 20-Aug-2015

·         Aurobindo gets final approval for Omeprazole
Aurobindo Pharma announced that the company has received the final approval from the US Food & Drug Administration ( USFDA) to manufacture and market Omeprazole Delayed-release Capsules USP, 10mg, 20mg and 40mg. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Prilosec® Delayed-release Capsules, 10mg, 20mg and 40mg of AstraZeneca Pharmaceuticals.

·          Aurobindo receives USFDA approval for Ibandronate
Aurobindo Pharma announced that the company has received final approvals from the US Food & Drug Administration ( USFDA) to manufacture and market Ibandronate Sodium Injection, 3mg/3mL (1mg/mL).
Ibandronate Sodium Injection, 3mg/3mL (1mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Boniva® Injection, 3mg/3mL (1mg/mL) of Hoffmann-La Roche, Inc. Ibandronate Sodium Injection is indicated for the treatment of osteoporosis in postmenopausal women.
                                                                                
·         Crude oil declines further; Brent at $47
Crude oil declined further; Brent at $47 and WTI at $ 40, new low - Positive for OMC’s , Paints, Lubricants and Tyre companies .Crude Oil ( Brent) has slipped again and is now trading below 5 year low at $ 46.92, while WTI Oil is hovering around $40. As a result the industries which use crude and its derivatives are expected to be beneficial. Positive for OMCs (HPCL, BPCL), Paint (Asian Paints) and lubricants (Castrol, Gulf oil lubricant)
·         Lupin gets USFDA nod for Fenofibrate tablets; stk jumps
Shares of Lupin surged over 8%, touching to Rs1939.9, after pharma major said it has received approval from USFDA for Fenofibrate tablets in dosages of 160 mg and 54 mg. Fenofibrate is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.

·         Ratnamani Metals bags new order worth Rs159.40 cr
Ratnamani Metals & Tubes has announced that the Company has bagged an order for supply of coated CS pipes from Reliance Gas Pipelines amounting to Rs159.40 crores (net of taxes and duties) to be completed in current financial year.

·         Somi Conveyor Beltings receives orders worth Rs40.14 cr
Somi Conveyor Beltings said that it has received purchase orders worth Rs40.137 crore from BHEL, L&T and ThyssenKrupp Industries. The company will supply conveyor belts and related material of various specifications, it said. The company has bagged order worth Rs14.751 crore from Bharat Heavy Electricals ( BHEL). The order worth Rs14.164 crore was received from Larsen & Tourbo ( L&T), it said.
In addition, ThyssenKrupp Industries India issued order worth Rs 11.222 million to the company.
                                                                                                   
·         JSW Steel to invest Rs5000 cr on capital expenditure
JSW Steel has said that it is planning to invest about Rs5,000 crore on various capital expenditure projects in this fiscal ending March 2016, as per reports.  Commenting on the issue, JSW Steel Chairman and Managing Director Sajjan Jindal told the media, 'The company is expected to invest approximately Rs 5,000 crore during FY16 on various capital expenditure programmes.'
                                                    
·         Sun Pharma gets USFDA approval for Ximino

Sun Pharma gets USFDA approval for Ximino: Positive for the company .Sun Pharma gets US FDA approval for Supplemental New Drug Application (sNDA) for Ximino. This approval further strengthens the Company’s branded dermatology portfolio in the US. It expects Ximino TM extended-release capsules to be available for patients during the fourth quarter of 2015.

Tuesday 11 August 2015

expr:content='data:blog.blogId' itemprop='blogId'/>

Closing Bell 11-aug

CS CLOSING BELL:
NIFTY SPOT DOWN 62@8462
SENSEX DOWN 235@27866
BANK NIFTY FUTURES DOWN 259@18700
HAVE A NICE DAY!

WWW.CAPITALSTARS.COM
+917316790000

 
DAILY NIFTY SMART MOVERS
  
SCRIPTS
PRICE
VOLUME             (IN 000’S)
PRE. CLOSE
CHANGE (%)
CHANGE (Rs.)
26640.00
69.83
26027.35
2.35
612.6
1111.00
3475.43
1086.00
2.30
25.00
540.05
1288.61
530.95
1.71
9.10
415.90
895.15
409.60
1.54
6.30
2606.60
1039.39
2572.10
1.34
34.50


DAILY NIFTY TOP LAGGARDS

SCRIPTS
PRICE
VOLUME (000’S)
PRE. CLOSE
CHANGE (%)
CHANGE (Rs.)
247.50
8464.09
261.15
-5.23
-13.65
268.95
38366.45
282.75
-4.88
-13.80
368.35
9451.21
385.70
-4.50
-17.35
103.10
4656.41
107.80
-4.36
-4.70
392.05
8236.70
407.95
-3.90
-15.90


 

Do U Want !!!!

Our Special Services

sensex-nifty-charts

 
Blogger Templates